The 32nd International Congress on Thrombosis and Haemostasis (ISTH) was held from 22-26 June 2024 in Bangkok, Thailand. As one of the high-level international academic events in the field of thrombosis and haemostasis, ISTH Congress hosted a series of presentations and symposia, covering a wide range of topics from basic research to clinical applications. More than 5,000 medical researchers, clinicians, and industry leaders from all over the world shared the latest research results, exchanged cutting-edge scientific discoveries, and explored ways to bring comprehensive preventive strategies for patients with thrombosis and bleeding disorders around the globe.
Wondfo's Breakthroughs in Coagulation Testing
As the only Chinese brand in the IVD industry in the congress, Wondfo demonstrated our strength in the field of coagulation testing, and gained the recognition from many experts and scholars for its new chemiluminescence platform-Smarlumi™ FC-2100, and the leading screening items for early thrombosis in China, the 4-Item Test: TAT, TM, PIC, and t-PAIC.
New Thrombosis Testing, Wondfo Solution Gains Recognition
"I haven't learned about these indicators before, and the current mainstream test is still based on D-Dimer." The hematologist from Berlin, Germany showed great interest in Wondfo's Thrombosis 4-Item Test (TAT, TM, PIC, t-PAIC) and hoped to explore how these new indicators helps assist diagnosis and treatment. Compared with traditional coagulation tests, thrombus markers can reflect the hypercoagulable state of the body at an earlier stage and provide early warning of thrombotic diseases. In 2020, Wondfo launched the Thrombus 4-Item Test, becoming the first product capable of simultaneously testing six thrombotic markers from a single blood sample using a single instrument, leading domestic industry.
One of the Saudi Arabia pediatricians showed great enthusiasm for Wondfo's coagulation testing solution. He noted that traditional laboratory tests can take hours to days to produce results. Fast results are significant for pediatric patients who need quick diagnostic decisions, such as in ER. In addition to praising Wondfo's Coagulation 4 Test Items (PT, APTT, FIB, TT) and ACT, he was also impressed by Immunofluorescence platform, pointing out that D-Dimer for POCT will help save a lot of time.
Racing for life, Wondfo will continue to drive high-quality development through scientific research innovation, striving to make biotechnology benefit all.
The first developed technology platform with various application scenarios, including infectious disease, fertility, DOA, etc.
50+ kinds of reagents and five high-performance devices, focusing on detecting cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and others.
Single-dose Chemiluminescense Immunoassay Platform
Wondfo optical blood coagulation analyzer is the first one in the world that can test PT, APTT, TT, FIB, and ACT simultaneously.
Our Blood Gas Analyzer BGA-102 can produce the result in 30s. Its advantages of portability, easy operation, durability, and high performance make it ideal for clinics, laboratories, and hospitals.
Wondfo Dry Chemistry Analyzer can test 16 items and provide the result within 2 minutes, ideal for the detection of cardiac markers, kidney function, liver function, pancreatitis, etc.
Ready-to-use lyophilized RT-PCR Reagent；
Wondfo PA-3600 IHC Staining System
Advanced rapid diagnostic test with WHO prequalification for infectious disease
The Future Intelligent Medical Assistant to Healthcare
Fight against the pandemic through continuous innovation
